Sentynl Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
420 Stevens Ave Ste 200, Solana Beach, C...Phone Number
(858) 314-4215Website
www.sentynl.comRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Sentynl Therapeutics
Sentynl Therapeutics is a San Diego-based commercial-stage specialty pharma company that specializes in acquiring, developing and launching unique products. The company was acquired by the Zydus Group in 2017. Sentynl's highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well differentiated products across a broad spectrum of therapeutic areas. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations, and industry guidelines.Explore more
Sentynl Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sentynl Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Sentynl Therapeutics recently announced quarterly report
Sentynl Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Sentynl Therapeutics launches new products
Check out if Sentynl Therapeutics is spiking on competitors!
Check if Sentynl Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Sentynl Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Sentynl Therapeutics
Click to see if Sentynl Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Sentynl Therapeutics
Compare insights from companies similar to Sentynl Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sentynl Therapeutics
$6.7M
11-50
Private
-
2011
GC
Grant CastorExecutive Vice President & Business Chief & Commercial Officer
Company Profile Activity
Activity Insights
Sentynl Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sentynl Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sentynl Therapeutics.
Sentynl Therapeutics Tech Stack
A closer look at the technologies used by Sentynl Therapeutics
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Sentynl Therapeutics News & Media
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
LONDON and SOLANA BEACH, Calif. and AHMEDABAD, India, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (Nasdaq: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited (“Zydus”), today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturinSentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome
Sentynl will acquire full rights to the investigational drug candidate, Progerinin (SLC-D011), adding to its commercial portfolio of rare and ultra-rare disease products AHMEDABAD, India and SOLANA BEACH, Calif., March 16, 2026 /PRNewswire/ -- Sentynl Therapeutics Inc. ("Sentynl"), a...Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
ZYCUBO® is now the first and only therapy approved for the treatment of Menkes disease in the United States SOLANA BEACH, Calif., Jan. 13, 2026 /PRNewswire/ -- Sentynl Therapeutics Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited ("Zydus...Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission
The investigational copper histidinate candidate receives new PDUFA Target Action Date of January 14, 2026 SOLANA BEACH, Calif., Dec. 15, 2025 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sentynl Therapeutics
Sign Up For FreeTo access detailed company insights
Sentynl Therapeutics is a San Diego-based commercial-stage specialty pharma company that specializes in acquiring, developing and launching unique products. The company was acquired by the Zydus Group in 2017. Sentynl's highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies. With a foc... Read More
